Neurogenic Orthostatic Hypotension: Treatments
Treatment of Neurogenic Orthostatic Hypotension
Treatment of Neurogenic Orthostatic Hypotension
Golodirsen is a phosphorodiamidate morpholino oligomer.
The Food and Drug Administration has granted Orphan Drug designation to STK-001 (Stoke Therapeutics) for the treatment of Dravet syndrome.
The Food and Drug Administration (FDA) has cleared Nerivio Migra (Theranica), a prescription smartphone-controlled device for the acute treatment of migraine with or without aura in adults who do not have chronic migraine.
Heritage Pharmaceuticals has initiated a voluntary recall of Amikacin Sulfate Injection, USP, 1g/4mL (250mg/mL) and Prochlorperazine Edisylate Injection, USP, 10mg/2mL (5mg/mL) after microbial growth was detected in 1 unreleased sublot of both products.
These products may prevent patients from seeking appropriate treatment.
Applying lessons learned from autism to brain cancer, researchers at the Johns Hopkins University have discovered why elevated levels of the protein NHE9 add to the lethality of the most common and aggressive form of brain cancer, glioblastoma.
Scientists from the Florida campus of The Scripps Research Institute (TSRI) have for the first time discovered a killing mechanism that could underpin a range of the most intractable neurodegenerative diseases, such as Alzheimers, Parkinsons, and ALS.
A new intermediate step and unexpected enzymatic activity in a metabolic pathway in the body, which could lead to new drug design for psychiatric and neurodegenerative diseases, has been discovered by researchers at Georgia State University.
Rapidly emerging technologies, novel imaging techniques, and the development of new therapies and new genes have given researchers and clinicians an extraordinary ability to explore the brain at the cellular, genetic, and neural levels.